SCHEMBL3640462

SCHEMBL3640462

COC(=O)c1cccc(Oc2ccc(N)cn2)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.64
MEN1 O00255 3/20 0.64
KMT2A Q03164 3/20 0.64
ALDH1A1 P00352 2/20 0.64
BRCA1 P38398 1/20 0.64
HBB P68871 1/20 0.64
HSD17B10 Q99714 1/20 0.64
L3MBTL1 Q9Y468 2/20 0.57
CASP3 P42574 1/20 0.48
SENP8 Q96LD8 1/20 0.48
SENP7 Q9BQF6 1/20 0.48
SENP6 Q9GZR1 1/20 0.48
POLB P06746 2/20 0.48
GAA P10253 1/20 0.47
MAPT P10636 1/20 0.47
MAPK1 P28482 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
LMNA P02545 1/20 0.47
PPARG P37231 2/20 0.46
HTT P42858 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6178868 0.86 KDM4E (0.63) KDM4EMEN1KMT2AALDH1A1BRCA1
SCHEMBL4745669 0.84 KDM4E (0.50) KDM4EMEN1KMT2AALDH1A1BRCA1
SCHEMBL3996398 0.84 L3MBTL1 (0.57) KDM4EMEN1KMT2AALDH1A1BRCA1
SCHEMBL19032083 0.84 L3MBTL1 (0.57) KDM4EMEN1KMT2AALDH1A1BRCA1
SCHEMBL2365700 0.84 L3MBTL1 (0.64) MEN1KMT2AALDH1A1L3MBTL1CASP3
SCHEMBL1589066 0.83 LMNA (0.65) KDM4EMEN1KMT2AALDH1A1BRCA1
SCHEMBL31646829 0.82 L3MBTL1 (0.54) KDM4EMEN1KMT2AALDH1A1L3MBTL1
SCHEMBL2365744 0.81 LMNA (0.73) ALDH1A1L3MBTL1POLBGAAMAPT
SCHEMBL5873911 0.80 SMN1; SMN2 (0.58) MEN1KMT2AALDH1A1L3MBTL1POLB
SCHEMBL3635549 0.80 MAPT (0.61) KDM4EMEN1KMT2AALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2162445-B1 HETEROBICYCLIC COMPOUNDS AS KINASE INHIBITORS TAKEDA PHARMACEUTICAL (JP) 2013-11-27 EP disclosed
US-8304557-B2 Fused heterocycle derivatives and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-11-06 US disclosed
US-8304557-B2 Fused heterocycle derivatives and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-11-06 US disclosed
EP-2162445-A1 HETEROBICYCLIC COMPOUNDS AS KINASE INHIBITORS Takeda Pharmaceutical Company Limited (JP) 2010-03-17 EP disclosed
US-20090163488-A1 FUSED HETEROCYCLE DERIVATIVES AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-25 US disclosed
US-20090163488-A1 FUSED HETEROCYCLE DERIVATIVES AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-25 US disclosed
WO-2008150015-A1 HETEROBICYCLIC COMPOUNDS AS KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-12-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090163488-A1 FUSED HETEROCYCLE DERIVATIVES AND USE THEREOF NOX3, NOX5, ZYX KDM4E 2148/4885MEN1 604/4885KMT2A 1404/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.